Revenue
2022
2023
2024
2025
NewAmsterdam Pharma Co N.V. (NAMS)
Price$25.40Cached quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $22.5M | $45.6M | $14.1M | $102.7M | — | — |
| Research & development | $141.8M | $151.4M | $159.4M | $86.7M | $29.0M | — |
| Operating expenses | $248.2M | $221.9M | $197.1M | $106.3M | $35.0M | — |
| Operating income | −$225.7M | −$176.3M | −$183.0M | −$3.6M | −$35.0M | — |
| Operating margin | −1,002.90% | −386.91% | −1,298.56% | −3.46% | — | — |
| EBITDA | −$225.5M | −$176.2M | −$182.9M | −$3.5M | −$35.0M | — |
| EBITDA margin | −1,001.92% | −386.66% | −1,298.21% | −3.45% | — | — |
| Net income | −$203.8M | −$241.6M | −$176.9M | −$22.6M | −$41.8M | — |
| Net profit margin | −905.74% | −530.25% | −1,255.76% | −22.04% | — | — |
| Basic EPSper basic share | -$1.72 | -$2.56 | -$2.15 | -$1.19 | -$3.81 | — |
| Diluted EPSper diluted share | -$1.72 | -$2.56 | -$2.15 | -$1.19 | -$3.81 | — |
Owners
Reported shareholders
15.37%of listed shares
Frazier Life Sciences Management, L.P.18.09M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Frazier Life Sciences Management, L.P. | 15.37%18.09M shares |
Capital World Investors | 10.40%12.23M shares |
ForGrowth NAP B.V. / Forbion Growth Opportunities Fund I Cooperatief U.A. / Forbion IV Management B.V. / Forbion Capital Fund IV Cooperatief U.A. / Forbion Growth Management B.V. | ≈9.06%10.66M shares |
FMR LLC | 8.79%10.34M shares |
RA CAPITAL MANAGEMENT, L.P. | 8.12%9.55M shares |
FCPM III SERVICES B.V. | 7.22%8.49M shares |
Topper James N | ≈5.80%6.83M shares |
DEERFIELD MANAGEMENT COMPANY, L.P. | 3.62%4.26M shares |
VIKING GLOBAL INVESTORS LP | 3.57%4.2M shares |
Bain Capital Life Sciences Investors, LLC | 3.24%3.81M shares |
MAVERICK CAPITAL LTD | 2.78%3.27M shares |
Duquesne Family Office LLC | 2.61%3.07M shares |
Jupiter Topco LLC | 2.16%2.54M shares |
Medicxi Ventures Management (Jersey) Ltd | 1.88%2.21M shares |
JENNISON ASSOCIATES LLC | 1.79%2.1M shares |
Orbis Allan Gray Ltd | 1.49%1.75M shares |
Polar Capital Holdings Plc | 1.47%1.72M shares |
Capital International Investors | 1.46%1.72M shares |
GOLDMAN SACHS GROUP INC | 1.31%1.54M shares |
WESTFIELD CAPITAL MANAGEMENT CO LP | 1.31%1.54M shares |
Percentages use 117.65M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 22, 2026Form 4 · 10b5-1 | Kooij Louise FrederikaChief Accounting Officer | SellOrdinary Shares | 300 | $30.73 | $9.2K | 24.4K |
| Jun 22, 2026Form 4 · 10b5-1 | Kooij Louise FrederikaChief Accounting Officer | SellOrdinary Shares | 39.7K | $30.20 | $1.20M | 24.7K |
| May 26, 2026Form 4 · 10b5-1 | Kooij Louise FrederikaChief Accounting Officer | SellOrdinary Shares | 65.0K | $35.69 | $2.32M | 24.4K |
| Mar 11, 2026Form 4 | LANGE LOUIS GDirector | SellOrdinary Shares | 446 | $31.23 | $13.9K | 10.4K |
| Mar 11, 2026Form 4 | LANGE LOUIS GDirector | SellOrdinary Shares | 44.2K | $30.41 | $1.34M | 10.8K |